phrykt

AgomAb Therapeutics NV (AGMB): who owns it and who trades it

As of Nov 16, 2026, AGMB insiders reported 16 purchases worth $549K in the last 12 months. The largest buyer was David R Epstein (Director), with $412K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling AgomAb Therapeutics NV

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AGMB

34 funds and institutions reported AGMB shares worth $357M at the end of Q2 2026, about 81% of the company. The largest holder is EQT Fund Management S.a r.l. with 15.0%.

Funds and institutions (13F) 81%Everyone else 19%

10 largest owners, by share of the company

EQT Fund Management S.a r.l.15.0%
Nantahala Capital Management, LLC9.2%
Sanofi8.1%
Redmile Group, LLC8.0%
Cormorant Asset Management, LP7.2%
TCG Crossover Management, LLC6.0%
Federated Hermes, Inc.4.7%
Casdin Capital, LLC4.5%
Andera Partners4.5%
FMR LLC (Fidelity)4.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
EQT Fund Management S.a r.l.5.14M15.05%$66.7MNo change
Nantahala Capital Management, LLC3.14M9.18%$40.7M+161%
Sanofi2.78M8.15%$36.1MNo change
Redmile Group, LLC2.73M8.00%$35.5M+1650%
Cormorant Asset Management, LP2.47M7.22%$32MNo change
TCG Crossover Management, LLC2.05M6.01%$26.7MNo change
Federated Hermes, Inc.1.62M4.74%$21MNo change
Casdin Capital, LLC1.55M4.54%$20.1MNo change
Andera Partners1.54M4.50%$20MNo change
FMR LLC (Fidelity)1.46M4.27%$18.9MNo change
Aberdeen Group plc846,6952.48%$11M+20%
Perceptive Advisors LLC600,0001.76%$7.8MNo change
Samsara Biocapital, LLC600,0001.76%$7.8MNo change
Siren, L.L.C.411,2501.20%$5.3MNo change
Orbimed Advisors LLC192,7400.56%$2.5MNew
Pfizer Inc75,0000.22%$1MNo change
Alps Advisors Inc49,9840.15%$649KNew
Bellevue Group AG49,2480.14%$639K-2%
Seven Grand Managers, LLC47,6000.14%$618K-76%
Sectoral Asset Management Inc43,5000.13%$565KNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AGMB insiders reported $549K of open-market purchases and $0 of sales.

Purchases, 12 months
$549K
16 trades, 3 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 16, 2026

Purchases and sales by month

$356K$356KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026David R EpsteinDirectorPurchase5,000$5.99$29.9KForm 4
Nov 13, 2026David R EpsteinDirectorPurchase20$6.00$120Form 4
Nov 13, 2026David R EpsteinDirectorPurchase5,000$5.75$28.8KForm 4
Nov 13, 2026David R EpsteinDirectorPurchase4,960$6.02$29.9KForm 4
Nov 5, 2026David R EpsteinDirectorPurchase5,000$6.81$34KForm 4
Nov 5, 2026David R EpsteinDirectorPurchase5,000$6.91$34.5KForm 4
Nov 5, 2026David R EpsteinDirectorPurchase5,000$6.98$34.9KForm 4
Oct 21, 2026David R EpsteinDirectorPurchase5,000$8.86$44.3KForm 4
Oct 21, 2026David R EpsteinDirectorPurchase5,000$8.90$44.5KForm 4
Oct 8, 2026David R EpsteinDirectorPurchase5,000$8.90$44.5KForm 4
Oct 6, 2026David R EpsteinDirectorPurchase5,000$8.70$43.5KForm 4
Oct 6, 2026Pierre Thadee Victor KemulaCFOPurchase3,000$8.67$26KForm 4
Oct 6, 2026Pierre Thadee Victor KemulaCFOPurchase5,000$8.57$42.9KForm 4
Oct 6, 2026Pierre Thadee Victor KemulaCFOPurchase2,000$8.54$17.1KForm 4
Oct 5, 2026David R EpsteinDirectorPurchase5,000$8.57$42.9KForm 4
Oct 5, 2026Tim Jasper KnotnerusCEOPurchase6,000$8.48$50.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
David R EpsteinDirector$412K–Nov 13, 2026
Pierre Thadee Victor KemulaChief Financial Officer$85.9K–Oct 6, 2026
Tim Jasper KnotnerusChief Executive Officer, Director$50.9K–Oct 5, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AGMB short interest

920,851 AGMB shares are sold short. Over the last 12 reports the number of shares short went up 19%.

As of Oct 30, 2026, 920,851 AGMB shares were sold short, down 2.2% from the report before. At the average daily volume of 123,797 shares, buying them all back would take about 7.4 trading days (days to cover).

Shares short, % of all shares

3.63%May 15Jul 153.84%

Days to cover

7.4May 15Oct 3020.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026920,851–-2%123,7977.4
Oct 15, 2026941,904–-6%177,9135.3
Sep 30, 20261.00M–+15%140,6787.1
Sep 15, 2026867,701–-1%188,4714.6
Aug 31, 2026878,372–-7%129,7856.8
Aug 14, 2026941,121–-22%121,5637.7
Jul 31, 20261.20M–-3%64,34518.7
Jul 15, 20261.24M3.63%-0%85,32714.6
Jun 30, 20261.24M3.64%+16%142,1818.7
Jun 15, 20261.07M3.13%+35%116,8079.2
May 29, 2026791,0462.32%+3%42,92518.4
May 15, 2026771,2662.26%+2%85,3629.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Famous investors that hold AGMB

2 of the 50 well-known investors we track reported holding AGMB in their latest 13F filing. The largest position is Steve Cohen's, worth $744K.

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 202667,032$744K0.0%New
Ken Griffin · Citadel AdvisorsQ3 202611,635$129K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named AGMB in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Redmile Group, LLC13G/A3.5%
Nov 16, 2026Redmile Group, LLC13G/A3.5%

Questions about AgomAb Therapeutics NV (AGMB) stock

Who owns the most AGMB stock?

The largest reported owner of AgomAb Therapeutics NV (AGMB) is EQT Fund Management S.a r.l., with 15.0% of the company. In total, 34 funds and institutions reported holding AGMB at the end of Q2 2026, together about 81% of the shares. See the largest owners.

Are AGMB insiders buying or selling?

In the last 12 months, AGMB insiders reported 16 open-market purchases worth $549K and no sales. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in AGMB?

As of Oct 30, 2026, 920,851 AGMB shares were sold short, down 2.2% from the report before. At the average daily volume of 123,797 shares, buying them all back would take about 7.4 trading days (days to cover). See the history.

Which famous investors hold AGMB?

2 of the 50 well-known investors we track reported AGMB in their latest 13F filing, including Steve Cohen, Ken Griffin. The largest position is worth $744K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.